Overall survival and progression-free survival from start of first-line and second-line IO and chemotherapy by STK11 mutation status (patients with non-squamous NSCLC).
收藏数据链接：
官方服务：
资源简介：
Overall survival and progression-free survival from start of first-line and second-line IO and chemotherapy by STK11 mutation status (patients with non-squamous NSCLC).
创建时间：
2020-09-03
